← All trials
NCT02463071
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 10, 2015
- Primary completion
- Mar 11, 2017
- Completion date
- Mar 11, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 886
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- Koyokai Nakajima HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.